Myers Michael 4

What Happened

• Michael Myers, CEO of Quoin Pharmaceuticals (QNRX), received a grant/award of derivative securities on Feb 4, 2026. The award covers 318,750 American Depositary Shares (ADSs) listed at $0.00 (derivative acquisition).
• The ADS-based award equals 11,156,250 ordinary shares underlying the ADSs (318,750 ADSs × 35 ordinary shares per ADS). No cash was paid for the award as reported.

Key Details

• Transaction date: 2026-02-04; Form 4 filed: 2026-02-06 (filed timely).
• Transaction type/code: A (grant/award of derivative securities); price reported: $0.00.
• Amount granted: 318,750 ADSs (represents 11,156,250 ordinary shares).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnotes: F1 — counts and exercise price are reported in ADS terms (1 ADS = 35 ordinary shares). F2 — the award is described with a vesting schedule: 20% vests Feb 4, 2027; 20% vests Feb 4, 2028; 20% vests Feb 4, 2029; 40% vests Feb 4, 2030.
• Filing timeliness: Report appears timely (filed two days after the grant).

Context

• The filing treats this as a derivative award (footnotes indicate it is an option-style grant with a multi-year vesting schedule). This is a compensation award rather than an open-market purchase or sale and does not indicate an immediate sale of shares.
• Executive awards are common for compensation and retention; they differ from insider purchases (which some investors view as a stronger bullish signal).